Nasdaq

bioMérieux: BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 Obtains FDA Emergency Use Authorization

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary ...
Nasdaq

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology ...
WRAL TechWire

BioMerieux to acquire BioFire Diagnostics for $450M

Diagnostics company bioMerieux has reached an agreement to acquire molecular biology company BioFire Diagnostics for $450 million in a move intended to strengthen the French company’s position in ...
FierceBiotech

BioMérieux's BioFire sets course for GI panel FDA clearance

Just a month out from being bought by French giant bioMérieux, BioFire Diagnostics took its FilmArray diagnostic system's new gastrointestinal option to the FDA for clearance, which the newly united ...
Business Wire

First of 3 Diagnostic Tests for SARS-CoV-2 Coronavirus Available from bioMérieux

MARCY L’ÉTOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to ...
FierceBiotech

BioMérieux to fork over $450M for Utah Dx outfit

French diagnostics developer bioMérieux is ponying up $450 million for the newly renamed BioFire Diagnostics, a move that helps consolidate its position in infectious disease testing with one ...